Oncocyte Corp
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
IMDX$2.47-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
| Three Months Ended | |||
|---|---|---|---|
| March 31, | |||
| 2024 · 2023 | |||
| Net revenue | $176 | $297 | |
| Cost of revenues | 252 | 265 | |
| Cost of revenues – amortization of acquired intangibles | 22 | 22 | |
| Gross (loss) profit | (98) | 10 | |
| Operating expenses: | |||
| Research and development | 2,169 | 2,127 | |
| Sales and marketing | 846 | 695 | |
| General and administrative | 2,673 | 3,412 | |
| Change in fair value of contingent consideration | 3,312 | (18,307) | |
| Impairment loss | - | 4,950 | |
| Impairment loss on held for sale assets | 169 | 1,283 | |
| Total operating expenses (credits) | 9,169 | (5,840) | |
| (Loss) income from operations | (9,267) | 5,850 | |
| Other (expenses) income: | |||
| Interest expense | (15) | (11) | |
| Unrealized gain on marketable equity securities | - | 121 | |
| Other income (expenses), net | 153 | (1) | |
| Total other income | 138 | 109 | |
| (Loss) income before income taxes | (9,129) | 5,959 | |
| Income taxes | - | - | |
| (Loss) income from continuing operations | (9,129) | 5,959 | |
| Loss from discontinued operations (Note 11) | - | (2,926) | |
| Net (loss) income | $(9,129) | $3,033 | |
| Net (loss) income per share: | |||
| Net (loss) income from continuing operations - basic and diluted | $(9,335) | $4,899 | |
| Net loss from discontinued operations - basic and diluted | $ | - | $(2,502) |
| Net (loss) income attributable to common stockholders - basic and diluted | $(9,335) | $2,397 | |
| Net (loss) income from continuing operations per share - basic and diluted | $(1.13) | $0.82 | |
| Net loss from discontinued operations per share - basic and diluted | $ | - | $(0.42) |
| Net (loss) income attributable to common stockholders per share - basic and diluted | $(1.13) | $0.40 | |
| Weighted average shares outstanding - basic | 8,264 | 5,958 | |
| Weighted average shares outstanding - diluted | 8,264 | 5,963 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.